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Received September 16, 2013; accepted April 10, 2014AbstractBackground: Esophageal cancer is the eighth most common malignancy and sixth most fatal disease worldwide. However, it is the fourth most
common cause of death in China. Although surgery is currently the recommended course of treatment, there are some patients that do not receive
radical treatment due to the presence of distant organ or lymph node metastasis. There is at present no established treatment standard for
esophageal cancer patients with distant organ metastasis. The purpose of this study was to investigate the prognostic factors involved in
determining survival of esophageal cancer patients with distant organ metastasis at initial diagnosis, and to provide a reference for the planning
of a clinical treatment strategy.
Methods: The data of 57 evaluable esophageal squamous cell carcinoma patients with distant organ metastasis at initial diagnosis were studied
retrospectively. The survival rate was calculated using the KaplaneMeier method, and the log-rank test was used to test the differences.
Multivariable analysis was performed using the Cox proportion hazards model.
Results: The median survival time for all patients was 6 months (range, 1e55 months), and the 1- and 2-year survival rates were 21.1% and
11.8%, respectively. The median survival time for patients with single metastasis was 10 months with 1- and 2-year survival rates of 47.4% and
28.1%, respectively. For patients with multiple metastases, the survival duration was 5 months, with 1- and 2-year survival rates of 7.9% and
3.9%, respectively ( p < 0.001). The 1- and 2-year survival rates with multimodality treatment were 70% and 45%, respectively, which were
significantly better than chemotherapy alone (13.3% and 8.9%, respectively, p ¼ 0.003) and best supportive care (5.9% and 0%, p < 0.001), but
there was no significant difference between the latter two groups ( p ¼ 0.061).
Conclusion: For esophageal squamous cell carcinoma patients with distant organ metastasis upon initial diagnosis, the presence of a single
metastasis appeared to favor overall survival compared to multiple metastases. Multimodality treatment may also improve patient survival, but
chemotherapy alone has not been established as a favorable prognostic factor.
Copyright © 2014 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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11. Introduction
Esophageal cancer has an extraordinary impact on world-
wide health, with ~460,000 new diagnoses and >380,000Conflicts of interest: The authors declare that there are no conflicts of interest
related to the subject matter or materials discussed in this article.
* Corresponding author. Dr. Ben-Hua Xu, Department of Radiation
Oncology, Fujian Medical University Union Hospital, 29, Xinquan Road,
Gulou district, Fuzhou City, Fujian Province 350001, China.
E-mail address: benhuaxu@163.com (B.-H. Xu).
http://dx.doi.org/10.1016/j.jcma.2014.05.014
1726-4901/Copyright © 2014 Elsevier Taiwan LLC and the Chinese Medical Assdeaths annually. It also has a significant effect on the health of
Chinese people, in whom it represents the fourth most com-
mon cause of death. Surgery is currently the mainstay of
esophageal cancer treatment; however, >30% of patients do
not qualify for surgical resection due to advanced cancer stage
or concomitant diseases.2 Furthermore, about 18% of patients
present with distant organ or lymph node metastasis and miss
the opportunity for radical treatment.3
Although there are numerous available case reports regarding
the treatment of newly diagnosed distant organ metastasis of
esophageal cancer,4,5 there is currently no established standardociation. All rights reserved.
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0.3% at 3 years and amedian survival time (MST) of 7months,6,7
treatment commonly includes palliative esophageal stent im-
plantation or improvement of symptoms by palliative chemo-
therapy and radiotherapy.
In the present study, the clinical data of 57 esophageal
squamous cell carcinoma patients with distant organ metas-
tasis at initial diagnosis were collected and retrospectively
reviewed. The outcomes were evaluated and the factors
affecting prognosis were analyzed to provide reference for the
planning of a clinical treatment strategy.
2. Methods2.1. Patient characteristicsThe data of 57 esophageal squamous cell carcinoma patients
with distant organ metastasis at initial diagnosis, who were
treated at Fujian Medical University Union Hospital, Fujian,
China between January 1, 2007 and December 31, 2010, were
collected. The retrospective analysis was approved by Fujian
Medical University Union Hospital Institutional Review Board.
All information had been anonymized and de-identified prior to
its analysis. The clinical characteristics of these patients are
summarized in Table 1. The patients included 47 men and 10
women (male: female ratio, 4.7:1), with a median age of 57
years (range, 37e78 years). All patients had been diagnosed
with squamous cell carcinoma. Furthermore, 50 (87.7%) pa-
tients had an Eastern Cooperative Oncology Group (ECOG)
score of 1. Pulmonary, hepatic, bone, brain, and gastric body
metastases were diagnosed in 29 patients, 17 patients, four
patients, one patient, and one patient, respectively, whereas five
patients presented with multiple organ metastases.2.2. Exclusion criteriaThe exclusion criteria were as follows: (1) history of other
tumors; (2) adenocarcinoma, neuroendocrine or small-cellTable 1
Clinical characteristics of 57 patients.
Median age, y (range) 57 (37e78)
Sex (M/F), n 47/10
ECOG performance status, n
0 19
1 31
2 7
Organ of metastasis (solitary-metastasis), n
Lung 29 (10)
Liver 17 (5)
Bone 4 (2)
Brain 1 (1)
Gastric body 1 (1)
Multiorgan 5
Treatment, n
Best supportive care 17
Chemotherapy alone 30
Surgery and chemotherapy 6
Radiotherapy and chemotherapy 4
ECOG ¼ Eastern Cooperative Oncology Group.esophageal carcinoma, or other malignant tumors of special
or uncertain biological behavior; and (3) other concomitant
medical condition requiring treatment.2.3. Pretreatment workup and diagnosis of metastasesThe pretreatment workup of all patients included a physical
examination, standard laboratory tests, chest radiography,
upper gastrointestinal endoscopy, barium swallow, cervical
and abdominal ultrasound, chest computed tomography (CT),
bone scan, and magnetic resonance imaging. Additionally,
bronchoscopy was performed if considered necessary. The
diagnostic criteria for metastasis were: (1) metastatic lesions
pathologically confirmed by surgical or biopsy samples; (2)
multiple metastases on CT or 18F-fluorodeoxyglucose positron
emission tomography/CT; and (3) a single metastatic lesion
confirmed by two or more types of imaging modalities. The
presence of a single metastatic lesion was defined as solitary
metastasis (19 patients; 33.3%), whereas two or more meta-
static lesions were defined as multiple metastases (38 patients;
66.7%).2.4. Statistical analysisAll patient outcomes were evaluated in December 2011.
Survival was calculated from the 1st day of treatment to the
date of death or the last follow-up. The survival data were
analyzed with SPSS software, version 17.0 (SPSS, Inc., Chi-
cago, IL, USA).
Survival curves were created with the KaplaneMeier
method and compared with the log-rank test. A multivariable
analysis by sex, age, ECOG score, metastasis site, number of
metastases, and treatment model was performed using the Cox
proportional hazards model. The relevant inspection level was
bilateral, where a 0.05.2.5. TreatmentThe patients were classified into three categories by treat-
ment method: best supportive care, chemotherapy alone, and
multimodality treatment (surgery combined with chemo-
therapy, or radiotherapy combined with chemotherapy; Table
1). Seventeen patients received best supportive care (2 cases,
esophageal stenting; 1 case, referred for gastric fistula; 1 case,
traditional Chinese medicine treatment; and 13 cases, nutri-
tional supportive treatment). Thirty patients received chemo-
therapy alone [6 cases, calcium folinate þ ftorafur þ
lobaplatin or oxaliplatin; 11 cases, taxol þ cisplatin (loba-
platin or oxaliplatin or nedaplatin); 4 cases, S1 þ lobaplatin; 1
case, gemcitabine þ cisplatin; 1 case, irinotecan þ cisplatin; 3
case, single-agent Xeloda or carmofur; and 4 cases, outpatient
chemotherapy]. The mean number of chemotherapy cycles
was 1.8 (range, 1e9 cycles). Multimodality treatment was
administered to 10 patients [6 cases, surgery þ chemotherapy
(5 cases, esophageal tumor resection and 1 case, esophageal
tumor and concomitant solitary lung metastasis resection); 4
cases, radiotherapy þ chemotherapy (1 patient underwent
1.0
0.8
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the primary esophageal tumor)].
3. Results
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Fig. 2. Overall survival curve for ECOG score, p ¼ 0.061. ECOG ¼ Eastern
Cooperative Oncology Group.At the latest follow-up, 46 patients had succumbed to the
disease and 11 patients remained alive. The MST for all the
patients was 6 months (range, 1e55 months) and the 1- and 2-
year survival rates were 21.1% and 11.8%, respectively
(Fig. 1).
The MST for patients with an ECOG score 1 (50/57;
87.7%) was 7 months (range, 1e55 months) with 1- and 2-
year survival rates of 22.0% and 13.6%, respectively. For
patients with an ECOG score 2 (7/57; 12.3%), the MST was
3 months (range, 1e13 months), whereas the 1- and 2-year
survival rates were 14.3% and 0%, respectively, without sig-
nificant heterogeneity ( p ¼ 0.061; Fig. 2).
The MST for solitary metastasis was 10 months (range,
1e55 months), with 1- and 2-year survival rates of 47.4% and
28.1%, respectively. For patients with multiple metastases, the
MST was 5 months (range, 1e17 months), with 1- and 2-year
survival rates of 7.9% and 3.9%, respectively. The difference
was considered to be statistically significant ( p < 0.001;
Fig. 3).
The MST for best supportive care was 5 months (range,
1e17 months), with 1- and 2-year survival rates of 5.9% and
0%, respectively. For chemotherapy alone, the MST was 7
months (range, 1e25 months) with 1- and 2-year survival rates
of 13.3% and 8.9%, respectively. For multimodality treatment,
the MST was 15.5 months (range, 5e55 months) with 1- and
2-year survival rates of 70% and 45%, respectively. The sur-
vival duration with multimodality treatment was superior to
that with best supportive therapy (c2 ¼ 15.402, p < 0.001) andO
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Fig. 1. Overall survival curve for all patients.chemotherapy alone (c2 ¼ 8.446, p ¼ 0.003). However, there
was no statistically significant difference between chemo-
therapy alone and best supportive care (c2 ¼ 3.509, p ¼ 0.061;
Fig. 4, Table 2).
There were no statistically significant differences in sur-
vival time with multimodality treatment of surgery combined
with chemotherapy, or radiotherapy combined with chemo-
therapy (c2 ¼ 2.106, p ¼ 0.147; Fig. 5). The multifactorial
analysis revealed that the number of metastases and multi-
modality treatments were independent prognostic factors andO
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Fig. 3. Overall survival curve for solitary-metastasis and multi-metastasis,
p < 0.001.
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Fig. 4. Overall survival curve for different treatment methods, the best sup-
portive care, chemotherapy alone, and multimodality treatment (multimodality
treatment vs. chemotherapy alone: c2 ¼ 8.446, p ¼ 0.003; multimodality
treatment vs. best supportive care: c2 ¼ 15.402, p < 0.001; and chemotherapy
vs. best supportive care: c2 ¼ 3.509, p ¼ 0.061).
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Fig. 5. Overall survival curve for multimodality treatment, p ¼ 0.147.
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(CI): 1.081e4.717] and 0.506 (95% CI: 0.347e0.738),
respectively.
4. Discussion
Esophageal cancer is one of the most common malig-
nancies occurring worldwide and is associated with a dismal
prognosis. Despite advances in surgical techniques, radio-
therapy technology, and novel chemotherapeutic agents widely
used over the past few years, the 5-year survival rate remains
20e30%.8 Local recurrence and distant metastasis are the
main causes of treatment failure. Upon development of distantTable 2
Survival in patients.
MST, mo
(range)
1-y
survival (%)
2-y
survival (%)
p
Metastasis number <0.001
Solitary 10 (1e55) 47.4 28.1
Multiple 5 (1e17) 7.9 3.9
ECOG score 0.061
1 7 (1e55) 21.6 13.3
2 3 (1e13) 14.3 0
Treatment
Best supportive care 5 (1e17) 5.9 0 <0.001a
Chemotherapy alone 7 (1e25) 13.3 8.9 0.003b
Multimodality
treatment
15.5 (5e55) 70 45 0.061c
Total 6.5 (1e55) 20.7 11.6
ECOG ¼ Eastern Cooperative Oncology Group; MST ¼ median survival time.
a Multimodality treatment vs. best supportive care.
b Multimodality treatment vs. chemotherapy alone.
c Chemotherapy vs. best supportive care.metastasis, treatment is difficult and the prognosis is poor,
with an MSTof 6 months, as demonstrated in this study, and 1-
and 2-year survival rates of only 21.1% and 11.8%,
respectively.
It was previously reported that the survival time of patients
with advanced cancer is correlated with their performance
status.9 In the present study, the survival of patients with an
ECOG score 1 was superior to that of patients with an
ECOG score 2, with an almost statistically significant dif-
ference ( p ¼ 0.061). Therefore, aggressive treatment is rec-
ommended for esophageal cancer patients with distant
metastases who exhibit a good performance status.10 Sanchez-
Munoz et al11 reported that, by improving the performance
status through nutritional support, the survival of patients with
an initially poor performance status may be improved when
combined with antitumor therapy.
Teo et al12 reported that the prognosis of nasopharyngeal
carcinoma with a solitary distant metastasis was distinctly
superior to that prognosis for patients with multiple metasta-
ses; however, there was no similar report on esophageal can-
cer. To the best of our knowledge, the present study was the
first to demonstrate that the survival duration of esophageal
cancer with a solitary distant metastasis was distinctly superior
to that with multiple distant organ metastases ( p < 0.001). The
multiple factor analysis indicated that the presence of multiple
metastases was an independent prognostic factor with the
mortality risk being 2.259 times that of solitary metastasis
(95% CI: 1.081e4.717). This suggested that, even in patients
with advanced esophageal cancer, solitary metastasis was
considered to be a favorable prognostic factor as opposed to
multiple metastases. Furthermore, upon multivariable analysis,
the metastatic site was not found to be an independent prog-
nostic factor, indicating that, regardless of the location,
esophageal cancer with a solitary metastasis should be treated
aggressively to improve the outcome of such patients in
clinical practice.
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treatment of patients with distant organ metastasis, despite the
fact that the number of Phase III clinical trials demonstrating
that chemotherapy alone may enhance the survival benefit of
patients with esophageal cancer is currently limited.13 The
present study demonstrated that, compared to the survival rate
of patients with best supportive care, the survival with
chemotherapy alone was almost statistically significantly
different ( p ¼ 0.061). This may be attributed to the following
reasons: (1) inadequate intensity of chemotherapy and unified
chemotherapy regimens; the mean number of chemotherapy
cycles was 1.8 and as many as six different chemotherapeutic
regimens were used in all the patients who received chemo-
therapy alone; and (2) the number of case studies was too
limited to achieve statistical significance. Thus, regarding
distant organ metastasis of esophageal cancer, the effect of
chemotherapy alone requires further investigation, particularly
for patients with a good performance status. However, the
appropriate combination of chemotherapy regimens and the
number of chemotherapeutic cycles require confirmation by
further clinical studies.
The present study revealed that survival with multimodality
treatment (surgery or radiotherapy combined with chemo-
therapy) was superior to that with chemotherapy alone or best
supportive care. A multifactorial analysis identified multi-
modality treatment as an independent factor affecting prog-
nosis, with a mortality risk ratio of 0.506 (95% CI:
0.347e0.738). This indicated that, on the basis of chemo-
therapy, the treatment of primary esophageal lesions may
improve the survival of esophageal cancer patients with distant
organ metastasis.14
With regards to multimodality treatment, the difference in
survival between surgery combined with chemotherapy and
radiotherapy combined with chemotherapy was not statisti-
cally significant ( p ¼ 0.147), suggesting that either surgery or
radiotherapy as a local treatment may be feasible for newly
diagnosed distant organ metastasis from esophageal cancer.15
However, due to the limited number of cases receiving mul-
timodality treatment, our results require confirmation through
the accumulation of more cases and further prospective clin-
ical trials.
In addition, in two different patterns of local multimodality
treatment groups, one patient in each group achieved long-term
survival following surgical resection of the metastatic lesions
following satisfactory control of the primary esophageal tumor,
indicating that the treatment of metastatic lesions, synchronous,
or asynchronous, may help improve survival.16,17
In conclusion, our study indicated that the number of
metastatic lesions and multimodality treatment are indepen-
dent prognostic factors in esophageal cancer with distant organ
metastasis at initial diagnosis, with solitary metastasis being
associated with a favorable prognosis. Furthermore, multi-
modality treatment may improve the survival of such patients.However, the benefit of chemotherapy alone requires further
investigation.
References
1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence,
mortality, and prevalence across five continents: defining priorities to
reduce cancer disparities in different geographic regions of the world. J
Clin Oncol 2006;24:2137e50.
2. Bancewicz J, Clark PI, Smith DB, Donnelly RJ, Fayers PM, Weeden S,
et al. Surgical resection with or without preoperative chemotherapy in
oesophageal cancer: a randomised controlled trial. Lancet
2002;359:1727e33.
3. Quint LE, Hepburn LM, Francis IR, Whyte RI, Orringer MB. Incidence
and distribution of distant metastases from newly diagnosed esophageal
carcinoma. Cancer 1995;76:1120e5.
4. Yamamoto T, Tachibana M, Kinugasa S, Yoshimura H, Nagasue N.
Esophagectomy and hepatic arterial chemotherapy following hepatic
resection for esophageal cancer with liver metastasis. J Gastroenterol
2001;36:560e3.
5. Hanazaki K, Kuroda T, Wakabayashi M, Sodeyama H, Yokoyama S,
Kusama J. Hepatic metastasis from esophageal cancer treated by surgical
resection and hepatic arterial infusion chemotherapy. Hepatogastroenter-
ology 1998;45:201e5.
6. Kato H, Tachimori Y, Watanabe H, Iizuka T. Evaluation of the new (1987)
TNM classification for thoracic esophageal tumors. Int J Cancer
1993;53:220e3.
7. Shimada H, Kitabayashi H, Nabeya Y, Okazumi S, Matsubara H,
Funami Y, et al. Treatment response and prognosis of patients after
recurrence of esophageal cancer. Surgery 2003;133:24e31.
8. Liu JF, Wang QZ, Hou J. Surgical treatment for cancer of the oesophagus
and gastric cardia in Hebei, China. Br J Surg 2004;91:90e8.
9. Bosaeus I. Nutritional support in multimodal therapy for cancer cachexia.
Support Care Cancer 2008;16:447e51.
10. Kim ST, Park KH, Oh SC, Seo JH, Shin SW, Kim JS, et al. Selection of a
patient subgroup with advanced esophageal squamous carcinoma who
could benefit from second-line chemotherapy. Oncology 2010;79:363e9.
11. Sanchez-Munoz A, Perez-Ruiz E, Saez MI, Trigo JM, Galindo MM,
Manzaneque L, et al. Limited impact of palliative chemotherapy on sur-
vival in advanced solid tumours in patients with poor performance status.
Clin Transl Oncol 2011;13:426e9.
12. Teo PM, Kwan WH, Lee WY, Leung SF, Johnson PJ. Prognosticators
determining survival subsequent to distant metastasis from nasopharyn-
geal carcinoma. Cancer 1996;77:2423e31.
13. Stahl M, Budach W, Meyer HJ, Cervantes A, Group EGW. Esophageal
cancer: Clinical Practice Guidelines for diagnosis, treatment and follow-
up. Ann Oncol 2010;21(Suppl 5):v46e9.
14. Tanaka T, Fujita H, Matono S, Nagano T, Nishimura K, Murata K, et al.
Outcomes of multimodality therapy for stage IVB esophageal cancer with
distant organ metastasis (M1-Org). Dis Esophagus 2010;23:646e51.
15. Iwase H, Shimada M, Nakamura M, Nakarai K, Iyo T, Kaida S, et al.
Concurrent chemoradiotherapy for locally advanced and metastatic
esophageal cancer: longterm results of a phase II study of UFT/CDDP
with radiotherapy. Int J Clin Oncol 2003;8:305e11.
16. Kosugi SI, Kanda T, Nishimaki T, Nakagawa S, Yajima K, Ohashi M,
et al. Successful treatment for esophageal carcinoma with lung metastasis
by induction chemotherapy followed by salvage esophagectomy: report of
a case. World J Gastroenterol 2006;12:4101e3.
17. Nakada T, Nagayama K, Hiramoto J, Tsuruta Y, Murakami S, Sakabe S.
Complete regression of esophageal cancer with concomitant liver
metastasis achieved by concurrent chemoradiation therapy. Int J Clin
Oncol 2002;7:192e6.
